

Performance of the beta-glucan test for the diagnosis of invasive fusariosis and scedosporiosis: a meta-analysis

Frederic Lamothe^{1,2,*} Marcio Nucci^{3,4} Ana Fernandez-Cruz⁵ Elie Azoulay⁶ Fanny Lanternier^{7,8} Jens Bremerich⁹ Hermann Einsele¹⁰ Elizabeth Johnson¹¹ Thomas Lehnbecher¹² Toine Mercier^{13,14} Luciana Porto¹⁵ Paul E. Verweij¹⁶ Lewis White¹⁷ Johan Maertens¹⁴ and Alexandre Alanio^{18,*} on behalf of the 9th European Conference on Infections in Leukemia (ECIL-9)

¹Infectious Diseases Service, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

²Institute of Microbiology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

³University Hospital, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

⁴Grupo Oncoclinicas, Brazil

⁵Infectious Disease Unit, Internal Medicine Department, Puerta de Hierro-Majadahonda University Hospital, Fundación de Investigación Puerta de Hierro-Segovia de Arana, Universidad Autónoma de Madrid, Madrid, Spain

⁶Médecine Intensive et Réanimation, APHP, Hôpital Saint-Louis, Paris Cité University, Paris, France.

⁷Institut Pasteur, Centre National de Référence Mycoses Invasives et Antifongiques, Groupe de recherche Mycologie Translationnelle, Département de Mycologie, Université Paris Cité, Paris, France

⁸Infectious Diseases Unit, Hôpital Necker Enfants malades, APHP, Necker-Pasteur Center for Infectious Diseases and Tropical Medicine, Paris, France

⁹Cardiothoracic Imaging Section, Department of Radiology, Basel University Hospital, 4031 Basel, Switzerland

¹⁰University Hospital Würzburg, Internal Medicine II, Würzburg, Germany

¹¹UK Health Security Agency (UKHSA) Mycology Reference Laboratory, Southmead Hospital, Bristol, UK and MRC Centre for Medical Mycology, Exeter University, Exeter, UK

¹²Division of Pediatric Hematology and Oncology, Hospital for Children and Adolescents, University Hospital, Johann Wolfgang Goethe University, Frankfurt am Main, Germany

¹³Department of Oncology-Hematology, AZ Sint-Maarten, Mechelen, Belgium

¹⁴Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven, Belgium and Department of Hematology, University Hospitals Leuven, Leuven, Belgium.

¹⁵Division of Neuroradiology, Pediatric Neuroradiology Department, University Hospital, Johann Wolfgang Goethe University, Frankfurt am Main, Germany

¹⁶Department of Medical Microbiology, Radboud University Center, Nijmegen, The Netherlands

¹⁷Public Health Wales Mycology Reference Laboratory and Cardiff University Centre for Trials Research/Division of Infection and Immunity, UHW, Cardiff, UK

¹⁸Parasitology-Mycology laboratory Department, AP-HP, Hôpital Saint-Louis, Paris, France

*To whom correspondence should be addressed. Frederic Lamothe, Infectious Diseases Service and Institute of Microbiology, Lausanne University Hospital, University of Lausanne, Rue du Bugnon 48, 1011 Lausanne, Switzerland. Tel: +41 21 314 11 11; E-mail: Frederic.Lamothe@chuv.ch; Alexandre Alanio, Laboratoire de parasitologie mycologie, Hôpital Saint Louis, Université Paris Cité Centre National de Référence Mycoses invasives et Antifongiques, Institut Pasteur, Paris France. Tel: +33142499501; E-mail: alexandre.alanio@pasteur.fr

Abstract

The (1→3)- β -D-glucan (BDG) is a component of the fungal cell wall that can be detected in serum and used as an adjunctive tool for the diagnosis of invasive mold infections (IMI) in patients with hematologic cancer or other immunosuppressive conditions. However, its use is limited by modest sensitivity/specificity, inability to differentiate between fungal pathogens, and lack of detection of mucormycosis. Data about BDG performance for other relevant IMI, such as invasive fusariosis (IF) and invasive scedosporiosis/lomentosporiosis (IS) are scarce.

The objective of this study was to assess the sensitivity of BDG for the diagnosis of IF and IS through systematic literature review and meta-analysis. Immunosuppressed patients diagnosed with proven or probable IF and IS, with interpretable BDG data were eligible. A total of 73 IF and 27 IS cases were included. The sensitivity of BDG for IF and IS diagnosis was 76.7% and 81.5%, respectively. In comparison, the sensitivity of serum galactomannan for IF was 27%. Importantly, BDG positivity preceded the diagnosis by conventional methods (culture or histopathology) in 73% and 94% of IF and IS cases, respectively. Specificity was not assessed because of lacking data. In conclusion, BDG testing may be useful in patients with suspected IF or IS. Combining BDG and galactomannan testing may also help differentiating between the different types of IMI.

Lay summary

IF and IS are severe fungal infections for which diagnosis is often delayed. This meta-analysis shows that beta-glucan testing in serum had a sensitivity of about 80% for IF/IS and could detect the disease earlier compared to conventional diagnostic tests.

Received: April 21, 2023. Revised: June 16, 2023. Accepted: June 26, 2023

© The Author(s) 2023. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Key words: *Fusarium*, *Scedosporium apiospermum*, *Lomentospora prolificans*, acute leukemia, transplant recipients, invasive fungal infections, beta-D-glucan.

Introduction

Invasive mold infections (IMI) are life-threatening complications in hematologic cancer patients, such as hematopoietic cell transplant recipients or patients receiving intensive chemotherapies for acute leukemia. While invasive aspergillosis and mucormycosis represent the most frequent IMI, invasive fusariosis (IF) and invasive scedosporiosis/lomentosporiosis (IS) account for about 3%–5% of IMI cases in Europe and the United States.^{1,2} This proportion varies geographically; for instance IF is more frequent in Brazil (15%–40% of IMI cases).^{3,4}

The diagnosis of IMI is difficult because it often requires invasive procedures such as bronchoscopy or tissue biopsy.⁵ Conventional diagnostic approaches (histopathology and culture) have low sensitivity.⁶ Non-culture tests for the detection of fungal antigens or DNA in serum are useful for the early detection of IMI. Specifically, *Aspergillus*-specific quantitative PCR and/or galactomannan (GM) testing in serum are recommended for the diagnosis of invasive aspergillosis.^{5,7} Quantitative PCR for Mucorales demonstrated appropriate performances for the diagnosis of mucormycosis in serum.⁸ However, diagnostic approaches for IF and IS are limited.⁹ Although blood cultures can detect *Fusarium* and *Scedosporium/Lomentospora* spp., their sensitivity is low (10%–40%).^{10,11} Non-culture methods for IF and IS mainly rely on different in-house panfungal PCRs, which are not standardized and not widely available.⁹ Recently, a specific PCR for *Fusarium* spp. detection in serum has been developed with promising results.¹² Although the GM test displays some cross-reaction with *Fusarium* spp., variable sensitivity results (10%–80%) for the diagnosis of IF in serum have been reported.^{12,13}

The (1→3)- β -D-glucan (BDG) is a polysaccharide of the fungal cell wall that can be detected in serum by different commercial kits.^{14,15} BDG testing is approved as a diagnostic tool for the diagnosis of IMI and other invasive fungal infections, such as invasive candidiasis and pneumocystosis.^{15,16} For invasive aspergillosis, an overall sensitivity of 50%–60% has been reported.^{15,17} While BDG testing is not recommended for mucormycosis, it may be useful for the diagnosis of other non-*Aspergillus* IMI, such as IF or IS.^{9,15} However, current data are scarce to assess its actual performance in this setting.

The objective of this study was to assess the sensitivity of BDG testing for the diagnosis of IF and IS in hematologic cancer patients and other immunocompromised populations (e.g., solid organ transplant recipients) by a systematic review of the literature and meta-analysis.

Methods

Search strategy and inclusion criteria

A systematic search of the literature was performed in PubMed database (<https://pubmed.ncbi.nlm.nih.gov>) using the following keywords: ‘beta-glucan’ or ‘glucan’ in combination with ‘*Fusarium*’, ‘*Scedosporium*’, ‘*Lomentospora*’, ‘fusariosis’, ‘scedosporiosis’, and ‘lomentosporiosis’. In addition, a systematic search of all case reports of *Fusarium*, *Scedosporium*, and *Lomentospora* infections was performed.

The papers were excluded on the basis of title/abstract according to the following exclusion criteria: (i) non-clinical studies or non-human infections, (ii) absence of host factors and/or no criteria of invasive fungal infections according to the European Organisation for Research and Treatment of Cancer and Mycoses Study Group Education and Research Consortium (EORTC-MSGERC),⁵ (iii) mixed or concomitant (<4 weeks apart) fungal infections, and (iv) articles in language other than English and for which additional data than those contained in the English abstract were required. Articles containing data about cases fulfilling EORTC-MSGERC criteria of proven or probable IF or IS in immunocompromised patients were screened for the term ‘glucan’. All cases for which individual clinical data were available and for which a result of BDG testing in serum by any validated method was reported were included.

Data collection

The following data were collected for each individual case: type of underlying disease and immunosuppressive conditions according to EORTC-MSGERC criteria, genus/species of the pathogenic fungus, localization of the fungal disease, presence or absence of fungemia (i.e., positive blood culture for *Fusarium* spp or *Scedosporium/Lomentospora* spp.), EORTC-MSGERC classification of the fungal infection, type of BDG test, quantitative value of serum BDG, and result of GM assay if available for IF cases. BDG results were interpreted according to the cut-off of positivity proposed by the manufacturer, which was ≥ 80 pg/ml for the FungitellTM assay (Associates of Cape Cod Inc., Falmouth, MA), ≥ 7 pg/ml for the Wako β -glucan test (FUJIFILM Wako Chemicals, Osaka, Japan) and ≥ 20 pg/ml for the Fungitec-G assay (Seikagaku, Tokyo, Japan). When the type of BDG assay was not mentioned in the original publication, the cases were included if the BDG result and its interpretation by the authors were not equivocal about the positivity or negativity of the result. Papers reporting only qualitative BDG results (‘positive’ or ‘negative’) were included. In case of multiple testing, the highest BDG value was considered. For IF, results of the GM test (Platelia *Aspergillus* EIA, Bio-Rad Laboratories, Marne-La-Coquette, France) were also collected when available. For studies reporting BDG results and for which individual data could not be collected, authors were contacted and additional data were obtained whenever possible.

Data analyses

Considering that most included publications were case reports or small case series, a specific tool was designed for the purpose of this meta-analysis in order to assess the quality and completeness of the data. For each included publication, the data were rated as ‘complete’ or ‘partially lacking’ regarding the characteristics of the patients (underlying diseases and immunosuppressive conditions), the characteristics of the fungal infection (EORTC-MSGERC classification, localization of infection), and the BDG data (type of BDG assay, quantitative and qualitative BDG result).




Figure 1. Algorithm for screening and selection of publications. BDG: (1→3)-β-D-glucan, EORTC-MSGERC: European Organisation for Research and Treatment of Cancer and Mycoses Study Group Education and Research Consortium, IFI: invasive fungal infection.

Sensitivity of BDG testing for the diagnosis of proven/probable IF and IS was calculated on the basis of all included cases and for different subgroups (adult vs. pediatric populations, hematologic cancer vs. other underlying conditions, neutropenia vs. no neutropenia, fungemia vs. no fungemia, and localized vs. disseminated infection). For IF, sensitivity of GM was also calculated and compared to that of BDG among cases for which both tests had been performed. For case reports and case-series providing data about the sequence leading to the diagnosis of IF or IS, the timing between the first positive BDG assay and the standard test confirming the diagnosis (culture or histopathology) was assessed.

Results

Invasive fusariosis (IF)

Of 985 publications screened, 39 met the inclusion criteria and were included in the meta-analysis (Fig. 1). Of these, 30 were single case reports and 9 were cohort studies for which individual BDG data were available (Supplementary Figure 1).^{12,18–55} Two of these cohorts accounted for a substantial number of cases ($n = 23$, 31.5%).^{12,43} In total, 73 cases of proven or probable IF in patients with EORTC-MSGERC host factors were included. The characteristics of the patients and IF cases are described in Table 1. The majority of patients had hematologic cancers (88%) and were neutropenic (64%). IF was proven in 90% and was associated with disseminated disease in 74% cases and fungemia in 51% cases. Identification of *Fusarium* spp. at species level was available for 48 (66%) cases and *Fusarium solani* complex accounted for 62.5% of them.

BDG was detected by the Fungitell assay in 53 (73%) cases and by the Wako or Fungitec-G assays in 5 (7%) cases and the type of test was not specified in the remaining 15 cases (21%). The BDG test was interpreted as positive in 56/73 cases leading to a sensitivity of 76.7% (Table 2). Subanalyses in differ-

ent subgroups did not show significant differences, although sensitivity tended to be higher in patients with disseminated IF and fungemia, and to be lower in the pediatric population (Table 2). No significant difference was observed between infections due to *F. solani* complex vs. other *Fusarium* spp. (73.3% vs. 88.9%, $P = 0.3$).

Concomitant results of GM testing were reported in 44 cases and were positive in 12 of them (sensitivity 27.3% compared to 71.0% for BDG).

The timing of BDG positivity compared to the diagnosis of IF obtained by histopathology or culture was assessed for 33 cases. BDG positivity preceded the positive culture/histopathology in 24 (73%) cases and was concomitant to it in 3 (9%) cases, while in 6 (18%) cases the first positive BDG result was obtained after IF diagnosis.

Invasive scedosporiosis/lomentosporiosis (IS)

Of 536 publications screened, 21 met the inclusion criteria and were included in the meta-analysis (Fig. 1). Of these, 18 were single case reports and 3 were cohort studies providing individual BDG data for a small number of cases (1–4 patients) (Supplementary Figure 1).^{18,23,56–74} In total, 27 cases of proven or probable IS (16 scedosporiosis, 10 lomentosporiosis, and 1 mixed infection) in patients with EORTC-MSGERC host factors were included. The characteristics of the patients and IS cases are described in Table 1. Most patients had hematologic cancers (59%) or solid-organ transplantation (30%). Neutropenia was reported in 26% of them, while 78% received immunosuppressive therapies. IS was proven in 85% cases with disseminated disease and fungemia in 44% and 30% cases, respectively. BDG was measured by the Fungitell assay in 13 (48%) cases, by the Wako or Fungitec-G assays in 7 (26%) cases, while the type of test was not specified in 7 cases (26%). The BDG test was interpreted as positive in 22/27 cases leading to a sensitivity of 81.5% (Table 2). Subanalyses in different subgroups did not show sig-

Table 1. Characteristics of patients and invasive fungal infections.

	Invasive fusariosis (N = 73) N (%)	Invasive scedosporiosis (N = 27) N (%)
Demographic characteristics		
Female/male/not specified	23 (32)/38 (52)/12 (16)	8 (30)/17 (63)/2 (7)
Adult (≥18 year old)/pediatric/not specified	56 (77)/12 (16)/5 (7)	24 (89)/2 (7)/1 (4)
Underlying diseases		
Hematologic cancer	64 (88)	16 (59)
Acute leukemia	31	6
Allogeneic HSCT	12	2
Other hematologic disease	21	8
Solid-organ transplantation	2 (3)	8 (30)
Other or not specified	7 (10)	3 (11)
Immunosuppressive conditions		
Neutropenia (yes/no/not specified)	47 (64)/5 (7)/21 (29)	7 (26)/17 (63)/3 (11)
Immunosuppressive therapy (yes/no/not specified) ¹	21 (29)/34 (47)/18 (25)	21 (78)/5 (19)/1 (4)
EORTC-MSGERC classification		
Proven/probable	66 (90)/7 (10)	23 (85)/4 (15)
Site of invasive fungal infection		
Single site/disseminated (>1 site)/not specified	14 (19)/54 (74)/5 (7)	15 (56)/12 (44)/0 (0)
Fungemia (yes/no/not specified)	37 (51)/32 (44)/4 (5)	8 (30)/19 (70)

EORTC-MSGERC: European Organisation for Research and Treatment of Cancer and Mycoses Study Group Education and Research Consortium, HSCT: hematopoietic stem cell transplantation

¹ Including mainly corticosteroids and calcineurin inhibitors.

Table 2. Sensitivity of BDG for the diagnosis of IF and IS.

	Overall	Adult Pediatric	Hematologic cancer Other conditions	Neutropenia No neutropenia	Fungemia No fungemia	Single site Disseminated
IF	56/73 (76.7)	46/56 (82.1) 8/12 (66.7)	48/64 (75.0) 5/6 (83.3)	37/47 (78.7) 4/5 (80.0)	30/37 (81.1) 23/32 (71.9)	10/14 (71.4) 43/54 (79.6)
IS	22/27 (81.5)	20/24 (83.3) 1/2 (50.0)	12/16 (75.0) 10/11 (90.9)	6/7 (85.7) 14/17 (82.4)	6/8 (75.0) 16/19 (84.2)	13/15 (86.7) 9/12 (75.0)

Number of cases with positive BDG/total number of cases (sensitivity in percentage)

nificant differences (Table 2). Results were similar between infections due *Lomentospora prolificans* vs. *Scedosporium apiospermum* complex (80.0% and 81.2% sensitivity, respectively).

The timing of BDG results could be assessed in 16 cases. BDG positivity was found to precede IS diagnosis by culture/histopathology in 15 (94%) cases and to be concomitant to it in one case.

Discussion

The use of BDG testing for the diagnosis of IMI is limited globally by its modest sensitivity (50%–70%) and limited specificity (80%–90%).^{15,75,76} A meta-analysis restricted to cohort studies of hematologic cancer patients showed a 50%–60% sensitivity of the BDG test in this setting.¹⁷ Moreover, a positive BDG cannot make the distinction between the different fungal pathogens. For these reasons, there is currently a weak recommendation to support the use of BDG testing for IMI diagnosis among patients with hematologic cancer or other immunosuppressive conditions and BDG has been removed from the mycological criteria of probable IMI in the updated revised EORTC-MSGERC definitions.^{5,7,15,77} More sensitive and more specific fungal biomarkers in serum, such as the GM test for invasive aspergillosis and specific quantitative PCRs for *Aspergillus* or Mucorales are usually recommended.^{5,7,8,77,78} However, there is currently no specific or validated assay for the diagnosis of IF or IS, although the

development of specific PCR looks to be a promising approach.¹²

While the BDG test is not specific for these fungal diseases, our meta-analysis suggests a relatively good sensitivity for the detection of IF (77%) and IS (82%), which is actually higher than that reported for IA (50%–60%).¹⁷ Considering a relatively low incidence (i.e., 1%–2%) of these IMI in high-risk populations, this would correspond to a negative predictive value >99.5%.

IF and IS are extremely severe IMI that should be promptly treated, thus requiring rapid diagnosis. While blood cultures can detect *Fusarium*, *Lomentospora*, and *Scedosporium* spp., their yield is limited (40%, 45%, and 6%, respectively) and the time to diagnosis is relatively long (2–3 days).^{11,79} It is important to note that BDG sensitivity remained high in our sub-analysis limited to non-fungemic cases (Table 2). Moreover, we showed that a positive BDG test preceded diagnosis by conventional methods (culture or histopathology) in a majority of cases. Therefore, BDG testing may represent an interesting diagnostic tool for the early detection of IF and IS, as prompt recognition and management of these severe diseases may improve their prognosis.

While the cross-reactivity of GM with *Fusarium* spp. is well described,^{13,38} our results indicate that GM sensitivity in serum for IF diagnosis was only 27%. Of note, these data were mainly derived from two case-series (Nucci et al. and Dellièrre et al.) displaying very distinct results with GM sensitivity of 77% (10/13 cases) and 0% (0/10 cases), respectively.^{12,43} Such

discrepancies might be related to the type of *Fusarium* spp. with better GM sensitivity in studies where *F. solani* predominates and lower sensitivity when there is a majority of other *Fusarium* spp.^{12,13,43} Of note, we did not observe a lower sensitivity of BDG among the non-*solani* *Fusarium* spp. in the present meta-analysis although their number was limited.

Although IF and IS represent the most frequent IMI after invasive aspergillosis and mucormycosis, other pathogenic molds (e.g., other hyalohyphomycetes, dematiaceous fungi) may be considered in case of a positive BDG result.²³ We could not assess the sensitivity of BDG for the detection of these rare molds because of the paucity of data. Some data suggest that BDG testing may also be useful for the diagnosis of endemic mycoses, such as histoplasmosis.⁸⁰

Some limitations of the present study should be outlined. First, the majority of the included publications consisted of single case reports, which may not be representative of the usual epidemiology and clinical presentation of these diseases. Inclusion of more severe and mostly proven IF or IS cases may have overestimated the sensitivity of BDG in this setting, but limits the uncertainty related to probable cases. Second, for IF, two cohort studies accounted for about one-third of cases (23/72),^{12,43} which may also represent a bias. Third, the quality of the selected publications is hampered by the use of diverse BDG kits with some lack of precision about the type of test or the quantitative results in some of them. Fourth, results of sub-analyses in different subgroups of patient should be interpreted cautiously (e.g., pediatric population) because of the small number of cases. Fifth, while ongoing antifungal prophylaxis may alter BDG sensitivity,⁴⁶ its impact could not be assessed in the present study because these data were lacking in about half of cases and only few of the remaining cases had received anti-mold prophylaxis. Sixth, while we could determine that BDG positivity preceded the diagnosis of proven IF or IS by culture or histopathology in a majority of cases, the information about the exact difference (i.e., number of days between first positive BDG result and culture/histopathology) was available for few of them. Moreover, these results may be biased by the fact that BDG was performed upon clinical suspicion and not as a screening strategy in most cases. Finally, the available dataset did not allow us to draw any conclusion about the specificity of BDG in this setting. Only one study reported data of BDG specificity for IF diagnosis using a small number ($N = 13$) of matched controls (same underlying conditions and no criteria of invasive fungal disease).⁴³ In this study, the specificity was 54%, which would result in a positive predictive value of only 5% considering the incidence of IF in this center. Important variations of BDG specificity have been reported across studies, which may be related to the type of patients' underlying conditions, the use of antifungal prophylaxis, and also possibly the handling of samples in the laboratory.^{15,81} A meta-analysis restricted to cohorts of adult hematologic cancer patients suggested an overall BDG specificity of about 90%, which could be increased to 99% with the requirement of two consecutive positive tests.¹⁷ However, specificity of BDG was shown to be lower (50%–70%) in non-hematologic cancer patients (e.g., solid-organ transplant recipients) or in children/neonates.^{82,83}

In conclusion, this systematic review and meta-analysis provides the largest dataset about the sensitivity of BDG testing in serum for the diagnosis of IF and IS. The good sensitivity suggests a high negative predictive value for these rare mold infections, although this should be interpreted cautiously in

the local epidemiological context and according to the level of clinical suspicion (pre-test probability). There is more concern about the specificity and positive predictive value, in particular, when the test is used in non-hematologic patients or as a screening test in high-risk hematologic patients. Therefore, BDG testing might be considered as an adjunctive diagnostic tool to rule out IF/IS in patients with low clinical suspicion or to guide antifungal therapy in patients with moderate/high clinical suspicion. Combining GM and BDG may also be useful for the distinction between different types of IMI (i.e., invasive aspergillosis, mucormycosis or other IMI such as IF or IS).

Supplementary material

Supplementary material is available at *Medical Mycology* online.

Author contributions

Frederic Lamoth (Conceptualization, Data curation, Formal analysis, Methodology, Supervision, Writing – original draft), Marcio Nucci (Data curation, Writing – review & editing), Ana Fernandez-Cruz (Data curation, Writing – review & editing), Elie Azoulay (Data curation, Writing – review & editing), Fanny Lanternier (Data curation, Writing – review & editing), Jens Bremerich (Conceptualization, Writing – review & editing), Hermann Einsele (Conceptualization, Writing – review & editing), Elizabeth Johnson (Conceptualization, Writing – review & editing), Thomas Lehrnbecher (Conceptualization, Writing – review & editing), Toine Mercier (Conceptualization, Writing – review & editing), Luciana Porto (Conceptualization, Writing – review & editing), Paul E. Verweij (Conceptualization, Writing – review & editing), Lewis White (Conceptualization, Writing – review & editing), Johan Maertens (Conceptualization, Writing – review & editing), and Alexandre Alanio (Conceptualization, Data curation, Formal analysis, Methodology, Supervision, Writing – review & editing)

Disclosures of conflict of interests

Frederic Lamoth has received research funding from Gilead, MSD, Pfizer and Novartis, has participated to advisory boards of Gilead, MSD and Pfizer, and has received honoraria for conferences from Gilead and Mundipharma. All contracts were made with and fees paid to his institution (CHUV).

Fanny Lanternier has participated to advisory board of F2G and has received honoraria for speaker bureau from Pfizer, Gilead and F2G.

Jens Bremerich has received funding from Boehringer-Ingelheim and has participated to advisory board of Guerbet, SA. All contracts were made with and fees paid to his institution.

Ana Fernandez-Cruz has received research funding from Gilead, all contracts were made with and fees paid to her institution.

Hermann Einsele discloses consulting or advisory role for BMS/Celgene, Janssen, Amgen, Takeda, Sanofi, GSK, Novartis, research funding from BMS/Celgene, Janssen, Amgen, GSK, Sanofi, honoraria from BMS/Celgene, Janssen, Amgen, Takeda, Sanofi, GSK, Novartis, and travel support from BMS/Celgene, Janssen, Amgen, Takeda, Novartis, Sanofi

Thomas Lehrnbecher served as a consultant to Gilead Sciences, Pfizer, Merck/MSD, Mundipharma, and Roche, and in the speaker's bureau of Gilead Sciences, Merck/MSD, EUSA Pharma, Pfizer, and Sanofi Pasteur.

Toine Mercier has received consultancy fees from Gilead Sciences, Pfizer, and AstraZeneca, an unrestricted research grant from Gilead Sciences, and travel support from AstraZeneca, Amgen, and Pfizer.

Johan Maertens reports grant support, personal fees and non-financial support from MDS, Pfizer Inc., and Gilead, personal fees and non-financial support from Basilea Pharmaceuticals, Mundipharma and F2G.

Alexandre Alanio has participated to advisory boards of Gilead and has received honoraria for conferences from Gilead and Pfizer and non-financial support from Gilead.

All other authors have no conflicts of interest to disclose.

Appendix

List of collaborators (participants to ECIL-9)

Robina AERTS, Murat AKOVA, Alexandre ALANIO, Diana AVERBUCH, Ola BLENNOW, Stéphane BRETAGNE, Alessandro BUSCA, Thierry CALANDRA, Simone CESARO, Catherine CORDONNIER, Rafael DE LA CAMARA, Caroline GARCIA-VIDAL, Lidia GIL, Andreas GROLL, Raoul HERBRECHT, Hans HIRSCH, Peter HUBACEK, Giuseppe INDOLFI, Csaba KASSA, Katrien LAGROU, Frederic LAMOTH, Thomas LEHRNBECHER, Per LJUNGMAN, Johan MAERTENS, Vincent MALLET, Rodrigo MARTINO, Varun MEHRA, Toine MERCIER, Malgorzata MIKULSKA, Marcio NUCCI, Livio PAGANO, Katia PERRUCCIO, Jose Luis PIÑANA, Luciana PORTO, Christine ROBIN, Emmanuel ROILIDES, Monica SLAVIN, Jan STYCZYNSKI, Frank TVERDEK, Paul VERWEIJ, Nadja Hawwa VISSING, Lewis WHITE, Alienor XHAARD, Olga ZAJAC SPYCHALA

References

- Bretagne S, Sitbon K, Desnos-Ollivier M et al. Active surveillance program to increase awareness on invasive fungal diseases: The French RESSIF Network (2012 to 2018). *mBio*. 2022; 13: e0092022.
- Kontoyiannis DP, Marr KA, Park BJ et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. *Clin Infect Dis*. 2010; 50: 1091-1100.
- Nucci M, Garnica M, Gloria AB et al. Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil. *Clin Microbiol Infect*. 2013; 19: 745-751.
- Souza L, Nouer SA, Morales H et al. Epidemiology of invasive fungal disease in haematologic patients. *Mycoses*. 2021; 64: 252-256.
- Donnelly JP, Chen SC, Kauffman CA et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. *Clin Infect Dis*. 2020; 71: 1367-1376.
- Lamoth F, Calandra T. Early diagnosis of invasive mould infections and disease. *J Antimicrob Chemother*. 2017; 72: i19-i28.
- Ullmann AJ, Aguado JM, Arikan-Akdagli S et al. Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline. *Clin Microbiol Infect*. 2018; 24 Suppl 1: e1-e38.
- Millon L, Caillot D, Berceanu A et al. Evaluation of serum *Mucorales* polymerase chain reaction (PCR) for the diagnosis of mucormycoses: The MODIMUCOR prospective trial. *Clin Infect Dis*. 2022; 75: 777-785.
- Tortorano AM, Richardson M, Roilides E et al. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: *Fusarium* spp., *scedosporium* spp. And others. *Clin Microbiol Infect*. 2014; 20 Suppl 3: 27-46.
- Nucci M, Barreiros G, Akiti T, Anaissie E, Nouer SA. Invasive fusariosis in patients with hematologic diseases. *J Fungi (Basel)*. 2021; 7:
- Seidel D, Meissner A, Lackner M et al. Prognostic factors in 264 adults with invasive *scedosporium* spp. And *lomentospora prolificans* infection reported in the literature and FungiScope((R)). *Crit Rev Microbiol*. 2019; 45: 1-21.
- Delliere S, Guitard J, Sabou M et al. Detection of circulating DNA for the diagnosis of invasive fusariosis: Retrospective analysis of 15 proven cases. *Med Mycol*. 2022; 60 (9).
- Nucci M, Carlesse F, Cappellano P et al. Earlier diagnosis of invasive fusariosis with Aspergillus serum galactomannan testing. *PLoS One*. 2014; 9: e87784.
- Alanio A, Gits-Muselli M, Guigue N et al. Prospective comparison of (1,3)-beta-D-glucan detection using colorimetric and turbidimetric assays for diagnosing invasive fungal disease. *Med Mycol*. 2021; 59: 882-889.
- Lamoth F, Akan H, Andes D et al. Assessment of the role of 1,3-beta-d-glucan testing for the diagnosis of invasive fungal infections in adults. *Clin Infect Dis*. 2021; 72: S102-S108.
- Alanio A, Hauser PM, Lagrou K et al. ECIL guidelines for the diagnosis of *Pneumocystis jirovecii* pneumonia in patients with haematological malignancies and stem cell transplant recipients. *J Antimicrob Chemother*. 2016; 71: 2386-2396.
- Lamoth F, Cruciani M, Mengoli C et al. beta-glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: A systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). *Clin Infect Dis*. 2012; 54: 633-643.
- Angebault C, Lanternier F, Dalle F et al. Prospective evaluation of serum beta-glucan testing in patients with probable or proven fungal diseases. *Open Forum Infect Dis*. 2016; 3: ofw128.
- Azoulay E, Guigue N, Darmon M et al. (1, 3)-beta-D-glucan assay for diagnosing invasive fungal infections in critically ill patients with hematological malignancies. *Oncotarget*. 2016; 7: 21484-21495.
- Bellanger AP, Grenouillet F, Henon T et al. Retrospective assessment of beta-D-(1,3)-glucan for presumptive diagnosis of fungal infections. *APMIS*. 2011; 119: 280-286.
- Biddeci G, Dona D, Geranio G et al. Systemic fusariosis: A rare complication in children with acute lymphoblastic leukemia. *J Fungi (Basel)*. 2020; 6:
- Brent G, Abdul-Wahab A, Borman AM et al. Disseminated bisi-fusarium infection following toxic epidermal necrolysis in a child with B-cell acute lymphoblastic leukemia. *Pediatr Dermatol*. 2023; 40 (3): 503-506.
- Cuetara MS, Alhambra A, Moragues MD et al. Detection of (1→3)-beta-D-glucan as an adjunct to diagnosis in a mixed population with uncommon proven invasive fungal diseases or with an unusual clinical presentation. *Clin Vaccine Immunol*. 2009; 16: 423-426.
- Dehal N, Quimby D. Disseminated fusariosis in a patient with acute myeloid leukemia: A case report. *Cureus*. 2019; 11: e5922.
- Fernandez-Cruz A, Semiglia MA, Guinea J et al. A retrospective cohort of invasive fusariosis in the era of antimould prophylaxis. *Med Mycol*. 2020; 58: 300-309.
- Fujishita K, Oka S, Kamei K et al. A disseminated *fusarium* *fujikuroi* species complex infection prior to allogeneic hematopoietic stem cell transplantation. *Acta Med. Okayama*. 2020; 74: 435-441.

27. Garcia RR, Min Z, Narasimhan S, Bhanot N. Fusarium brain abscess: Case report and literature review. *Mycoses*. 2015; 58: 22–26.
28. Garcia-Ruiz JC, Olazabal I, Adan Pedroso RM et al. Disseminated fusariosis and hematologic malignancies, a still devastating association. Report of three new cases. *Rev Iberoam Micol*. 2015; 32: 190–196.
29. Gupta S, Almyroudis NG, Battiwalla M et al. Successful treatment of disseminated fusariosis with posaconazole during neutropenia and subsequent allogeneic hematopoietic stem cell transplantation. *Transpl Infect Dis*. 2007; 9: 156–160.
30. Hoshino A, Tokoro S, Akashi T et al. Disseminated fusariosis in a child after haploidentical hematopoietic stem cell transplantation. *Pediatr Int*. 2020; 62: 419–420.
31. Hu CH, Curry EJ, Matzkin EG et al. Monoarthritis in a 28-year-old man with juvenile idiopathic arthritis. *Arthritis Care Res (Hoboken)*. 2015; 67: 1328–1334.
32. Inano S, Kimura M, Iida J, Arima N. Combination therapy of voriconazole and terbinafine for disseminated fusariosis: Case report and literature review. *J Infect Chemother*. 2013; 19: 1173–1180.
33. Jabr R, Liesman RM, Sethapati VR et al. Disseminated infection due to neocosmospora (*Fusarium*) *falciformis* in a patient with acute myelogenous leukemia. *Kans J Med*. 2022; 15: 67–69.
34. Kao AS, Cramer-Bour C, Kupsky W, Soubani AO. Endophthalmitis as the initial manifestation of invasive fusariosis in an allogeneic stem cell transplant patient: A case report. *Med Mycol Case Rep*. 2023; 40: 5–7.
35. Kawashima N, Yoshida N, Matsushita N et al. Intra-articular injection of voriconazole for *Fusarium solani* arthritis after bone marrow transplantation. *J Infect*. 2012; 65: 366–367.
36. Koltze A, Rath P, Schoning S et al. beta-D-glucan screening for detection of invasive fungal disease in children undergoing allogeneic hematopoietic stem cell transplantation. *J Clin Microbiol*. 2015; 53: 2605–2610.
37. Konuma T, Takahashi S, Kiyuna T et al. Fungemia due to *Fusarium solani* under low-dose liposomal amphotericin B in a patient after cord blood transplantation. *J Infect Chemother*. 2019; 25: 635–638.
38. Mikulska M, Furfaro E, Del Bono V et al. Galactomannan testing might be useful for early diagnosis of fusariosis. *Diagn Microbiol Infect Dis*. 2012; 72: 367–369.
39. Miyazaki M, Miyakoshi S, Kami M et al. Systemic fusariosis after a preparative regimen including thiopeta, VP-16 and busulfan used for blood stem cell transplantation in Hodgkin's disease. *Leuk Lymphoma*. 2001; 40: 441–444.
40. Nakai K, Yoneda K, Imataki O et al. Transepidermal growth in disseminated *Fusarium* infection. *J Dermatol*. 2014; 41: 770–771.
41. Ning JJ, Li XM, Li SQ. Disseminated *Fusarium* bloodstream infection in a child with acute myeloid leukemia: A case report. *World J Clin Cases*. 2021; 9: 6049–6055.
42. Nishio H, Sakakibara-Kawamura K, Suzuki T, Utsumi T, Kinoshita S. [An autopsy case of Ph1-positive acute lymphoblastic leukemia with disseminated infection of *Fusarium solani*]. *Kansenshogaku Zasshi*. 2002; 76: 67–71.
43. Nucci M, Barreiros G, Reis H et al. Performance of 1,3-beta-D-glucan in the diagnosis and monitoring of invasive fusariosis. *Mycoses*. 2019; 62: 570–575.
44. Odabasi Z, Mattiuzzi G, Estey E et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: Validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. *Clin Infect Dis*. 2004; 39: 199–205.
45. Okada H, Hamatani S, Kondo M et al. Successful treatment of disseminated *Fusarium* infection in an infant with leukemia. *Int J Hematol*. 2000; 72: 494–498.
46. Ostrosky-Zeichner L, Alexander BD, Kett DH et al. Multicenter clinical evaluation of the (1→3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. *Clin Infect Dis*. 2005; 41: 654–659.
47. Patterson TF, Mackool BT, Gilman MD, Piris A. Case records of the Massachusetts General Hospital. Case 22-2009. A 59-year-old man with skin and pulmonary lesions after chemotherapy for leukemia [corrected]. *N Engl J Med*. 2009; 361: 287–296.
48. Ricna D, Lengerova M, Palackova M et al. Disseminated fusariosis by *Fusarium proliferatum* in a patient with aplastic anaemia receiving primary posaconazole prophylaxis—case report and review of the literature. *Mycoses*. 2016; 59: 48–55.
49. Risum M, Overgaard UM, Rubek N et al. Disseminated fusariosis with cerebral involvement in a patient with acute myeloid leukemia: Successful outcome with intrathecal- and systemic antifungal treatment. *J Infect Chemother*. 2022; 28: 1324–1328.
50. Rose SR, Vallabhajosyula S, Velez MG et al. The utility of bronchoalveolar lavage beta-D-glucan testing for the diagnosis of invasive fungal infections. *J Infect*. 2014; 69: 278–283.
51. Sheela S, Ito S, Strich JR et al. Successful salvage chemotherapy and allogeneic transplantation of an acute myeloid leukemia patient with disseminated *Fusarium solani* infection. *Leuk Res Rep*. 2017; 8: 4–6.
52. Szvalb AD, Kontoyiannis DP. Acute acalculous cholecystitis due to *Fusarium* species and review of the literature on fungal cholecystitis. *Mycoses*. 2019; 62: 847–853.
53. Uemura S, Tamura A, Yamamoto N et al. Successful combination therapy of liposomal amphotericin B and caspofungin for disseminated fusariosis in a pediatric patient with acute lymphoblastic leukemia. *Pediatr Infect Dis J*. 2018; 37: e251–e253.
54. Yoshida M, Kiyota N, Maruyama K et al. Endogenous *Fusarium* endophthalmitis during treatment for acute myeloid leukemia, successfully treated with 25-gauge vitrectomy and antifungal medications. *Mycopathologia*. 2018; 183: 451–457.
55. Yoshida M, Obayashi T, Iwama A et al. Detection of plasma (1 → 3)-beta-D-glucan in patients with *Fusarium*, *Trichosporon*, *saccharomyces* and *acromonium* fungaemias. *J Med Vet Mycol*. 1997; 35: 371–374.
56. Boursillon B, Cipriano A, Regamey J et al. Case report: Disseminated *scedosporium apiospermum* infection with invasive right atrial mass in a heart transplant patient. *Front Cardiovasc Med*. 2022; 9: 1045353.
57. Bronnimann D, Garcia-Hermoso D, Dromer F, Lanternier F, French Mycoses Study G. Characterization of the isolates at the N. Scedosporiosis/lomentosporiosis observational study (SOS): Clinical significance of *scedosporium* species identification. *Med Mycol*. 2021; 59: 486–497.
58. Gao S, Ma X, Kang Y et al. Brain abscess caused by *Scedosporium boydii* in a systemic lupus erythematosus patient: A case report and literature review. *Indian J Med Microbiol*. 2022; 40: 611–615.
59. Garnham K, Halliday CL, Rai NJ et al. Introducing 1,3-beta-D-glucan for screening and diagnosis of invasive fungal diseases in Australian high-risk haematology patients: Is there a clinical benefit? *Intern Med J*. 2022; 52: 426–435.
60. Inoda S, Sato Y, Arai Y et al. [Bilateral Endogenous Fungal Subretinal Abscesses due to *Scedosporium prolificans*: a Case Report]. *Nippon Ganka Gakkai Zasshi*. 2015; 119: 632–639.
61. Kondo M, Goto H, Yamanaka K. Case of *scedosporium aurantiacum* infection detected in a subcutaneous abscess. *Med Mycol Case Rep*. 2018; 20: 26–27.
62. Levesque E, Rizk F, Noorah Z et al. Detection of (1,3)-beta-D-glucan for the diagnosis of invasive fungal infection in liver transplant recipients. *Int J Mol Sci*. 2017; 18: 862.
63. Mitomo H, Sakurada A, Matsuda Y et al. Endobronchial topical amphotericin B instillation for pulmonary chromomycosis after lung transplantation: A case report. *Transplant Proc*. 2018; 50: 939–942.
64. Nishimori M, Takahashi T, Suzuki E et al. Fatal fungemia with *scedosporium prolificans* in a patient with acute myeloid leukemia. *Med Mycol J*. 2014; 55: E63–70.
65. Ochi Y, Hiramoto N, Takegawa H et al. Infective endocarditis caused by *scedosporium prolificans* infection in a patient with

- acute myeloid leukemia undergoing induction chemotherapy. *Int J Hematol*. 2015; 101: 620–625.
66. Ochiai N, Shimazaki C, Uchida R et al. Disseminated infection due to *scedosporium apiospermum* in a patient with acute myelogenous leukemia. *Leuk Lymphoma*. 2003; 44: 369–372.
 67. Ohashi R, Kato M, Katsura Y et al. Breakthrough lung *scedosporium prolificans* infection with multiple cavity lesions in a patient receiving voriconazole for probable invasive aspergillosis associated with monoclonal gammopathy of undetermined significance (MGUS). *Med Mycol J*. 2011; 52: 33–38.
 68. Saini V, Shah A, Jaber T et al. *Scedosporium apiospermum* mediastinitis in an orthotopic heart transplant recipient. *IJID Reg*. 2022; 5: 117–120.
 69. Sakata Y, Taga F, Ushigami T et al. A case of cutaneous mycosis caused by *scedosporium dehoogii* on an immunocompromised patient. *Mycopathologia*. 2018; 183: 465–470.
 70. Suzuki Y, Oishi H, Matsuda Y et al. Pneumonia with *scedosporium apiospermum* and *lomentspora prolificans* in a patient after bilateral lung transplantation for pulmonary hypertension: A case report. *Transplant Proc*. 2021; 53: 1375–1378.
 71. Takeuchi M, Yoshida C, Ota Y, Fujiwara Y. Deep skin infection of *scedosporium apiospermum* in a patient with refractory idiopathic thrombocytopenic purpura. *Intern Med*. 2011; 50: 1339–1343.
 72. Tamaki M, Nozaki K, Onishi M et al. Fungal meningitis caused by *Lomentospora prolificans* after allogeneic hematopoietic stem cell transplantation. *Transpl Infect Dis*. 2016; 18: 601–605.
 73. Uno K, Kasahara K, Kutsuna S et al. Infective endocarditis and meningitis due to *scedosporium prolificans* in a renal transplant recipient. *J Infect Chemother*. 2014; 20: 131–133.
 74. Yu Z, Hu L, Jiang M et al. Dermatic *scedosporium apiospermum* infection after autologous bone marrow transplantation. *Intern Med*. 2013; 52: 689–693.
 75. Karageorgopoulos DE, Vouloumanou EK, Ntziora F et al. beta-D-glucan assay for the diagnosis of invasive fungal infections: A meta-analysis. *Clin Infect Dis*. 2011; 52: 750–770.
 76. Onishi A, Sugiyama D, Kogata Y et al. Diagnostic accuracy of serum 1,3-beta-D-glucan for pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: Systematic review and meta-analysis. *J Clin Microbiol*. 2012; 50: 7–15.
 77. Marchetti O, Lamoth F, Mikulska M et al. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. *Bone Marrow Transplant*. 2012; 47: 846–854.
 78. Mengoli C, Cruciani M, Barnes RA, Loeffler J, Donnelly JP. Use of PCR for diagnosis of invasive aspergillosis: Systematic review and meta-analysis. *Lancet Infect Dis*. 2009; 9: 89–96.
 79. Nucci M, Anaissie E. *Fusarium* infections in immunocompromised patients. *Clin Microbiol Rev*. 2007; 20: 695–704.
 80. Saccente M, Krishnan G. Comparison of blood (1→3)-beta-d-glucan levels in AIDS-related pneumocystis jirovecii pneumonia and AIDS-related progressive disseminated histoplasmosis. *Clin Infect Dis*. 2021; 73: 1100–1102.
 81. Lamoth F, Alexander BD. Nonmolecular methods for the diagnosis of respiratory fungal infections. *Clin Lab Med*. 2014; 34: 315–336.
 82. Alexander BD, Smith PB, Davis RD, Perfect JR, Reller LB. The (1,3)beta-D-glucan test as an aid to early diagnosis of invasive fungal infections following lung transplantation. *J Clin Microbiol*. 2010; 48: 4083–4088.
 83. Ferreras-Antolin L, Borman A, Diederichs A, Warris A, Lehrnbecher T. Serum beta-D-glucan in the diagnosis of invasive fungal disease in neonates, children and adolescents: A critical analysis of current data. *J Fungi (Basel)*. 2022; 8 (12): 1262.